ArticleMediators of inflammation2016
Interferon Tau Affects Mouse Intestinal Microbiota and Expression of IL-17.
Article in Mediators of inflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Nutraceuticals and pharmacological to balance the transitional microbiome to extend immunity during COVID-19 and other viral infections.Journal of translational medicine · 2024Review
- Article
- Predictive and Prognostic Roles of Gut Microbial Variation in Liver Transplant.Frontiers in medicine · 2022Review
- Fecal microbiota changes in NZB/W F1 mice after induction of lupus disease.Scientific reports · 2021Article
- HLA Class II Polymorphisms Modulate Gut Microbiota and Experimental Autoimmune Encephalomyelitis Phenotype.ImmunoHorizons · 2021Article
- The Correlation between Gut Microbiota and Serum Metabolomic in Elderly Patients with Chronic Heart Failure.Mediators of inflammation · 2021Article
- Effects ofFrontiers in nutrition · 2021Article
- Effect of nicotinamide riboside on lipid metabolism and gut microflora-bile acid axis in alcohol-exposed mice.Food science & nutrition · 2021Article
- Gut Microbiota Dysbiosis-Immune Hyperresponse-Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches.Microorganisms · 2020Review
- Article
- Gut Microbiota and IL-17A: Physiological and Pathological Responses.Probiotics and antimicrobial proteins · 2019Review
- TLR4 May Be Involved in the Regulation of Colonic Mucosal Microbiota by Vitamin A.Frontiers in microbiology · 2019Article
- Intestinal microbiota mediates Enterotoxigenic Escherichia coli-induced diarrhea in piglets.BMC veterinary research · 2018Article
- The cytosolic sensor STING is required for intestinal homeostasis and control of inflammation.Mucosal immunology · 2018Article
- Probiotic Species in the Modulation of Gut Microbiota: An Overview.BioMed research international · 2018Review
- Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury.Scientific reports · 2017Article
- T Cells in Osteoarthritis: Alterations and Beyond.Frontiers in immunology · 2017Review
- Chitosan Modulates Inflammatory Responses in Rats Infected with EnterotoxigenicMediators of inflammation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was conducted to explore the effects of interferon tau (IFNT) on the intestinal microbiota and expression of interleukin 17 (IL-17) in the intestine of mice. IFNT supplementation increased microbial diversity in the jejunum and ileum but decreased microbial diversity in the feces. IFNT supplementation influenced the composition of the intestinal microbiota as follows: (1) decreasing the percentage of Firmicutes and increasing Bacteroidetes in the jejunum and ileum; (2) enhancing the percentage of Firmicutes but decreasing Bacteroidetes in the colon and feces; (3) decreasing Lactobacillus in the jejunum and ileum; (4) increasing the percentage of Blautia, Bacteroides, Alloprevotella, and Lactobacillus in the colon; and (5) increasing the percentage of Lactobacillus, Bacteroides, and Allobaculum, while decreasing Blautia in the feces. Also, IFNT supplementation decreased the expression of IL-17 in the intestines of normal mice and of an intestinal pathogen infected mice. In conclusion, IFNT supplementation modulates the intestinal microbiota and intestinal IL-17 expression, indicating the applicability of IFNT to treat the intestinal diseases involving IL-17 expression and microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.